do growth-hormone peptides make you taller?

updated

safety first: every trial here enrolled children with diagnosed growth problems, and the one approved IGF-1 drug is ruled out for growth once growth plates close.

verdict: no evidence in healthy people; studied only in diagnosed growth problems (pediatric disorder data / healthy-height trials absent)

quick answer

there is no trial evidence that they make a healthy teen or adult taller. the trials enrolled children diagnosed with GH deficiency, severe IGF-1 deficiency or short stature, and the one approved drug here, mecasermin (Increlex), is labeled only for growth failure in children aged two and older with severe primary IGF-1 deficiency, or with a GH gene deletion and neutralizing antibodies to GH, and should not be used to promote growth once the growth plates (epiphyses) have closed. PubMed and ClinicalTrials.gov searches on 24 October 2026 found no height trial of these compounds in healthy children, teens or adults.

the evidence

the pediatric record is real and narrow. (supported)

mecasermin (Increlex) is labeled for growth failure in children with severe primary IGF-1 deficiency. sermorelin (Geref) was FDA-approved in 1997 for idiopathic GH deficiency in children with growth failure; the maker discontinued it, FDA withdrew the approval in 2009 and later found it was not withdrawn for safety or effectiveness reasons. in an open-label study with no comparison group, mean height velocity rose during a year of sermorelin in the 86 of 110 previously untreated prepubertal GH-deficient children eligible for efficacy analysis, and in randomized comparisons growth hormone itself matched or beat sermorelin.

the secretagogue trials are small, sponsor-run or negative. (gap)

oral LUM-201, which is ibutamoren (MK-677), a nonpeptide, is in trials run by its sponsor in prepubertal children with GH deficiency. phase 2 trials NCT04614337 and NCT05250063 are completed; in the first, every LUM-201 group grew more slowly over six months, on average, than children on daily growth hormone injections. phase 3 NCT06948214 has been recruiting since 20 May 2026. older GHRP-2 and hexarelin studies in short children were small and uncontrolled, and a placebo-controlled trial of a GHRP-2 nasal spray in 126 children with GH deficiency found no growth difference.

for a healthy teen, the documented side is risk. (risk)

the Increlex label warns of severe hypoglycemia with seizures, raised pressure inside the skull, slipped capital femoral epiphysis (a hip problem that can occur with rapid growth) and malignancies reported after marketing, whose link to the drug is unknown. FDA found undeclared ibutamoren in a growth product sold for children aged five and older and warned that it may increase the potential for congestive heart failure in certain individuals. PubMed and ClinicalTrials.gov searches on 24 October 2026 found no height study in people for CJC-1295, ipamorelin, tesamorelin or IGF-1 LR3.

bottom line

for a healthy teen these compounds carry documented risks and no documented height gain; the approved IGF-1 treatment should be supervised by a physician experienced in pediatric growth disorders.

scores

  • human height trials in healthy people: 0 · none located in PubMed or ClinicalTrials.gov on 24 October 2026; the trials cited enrolled children with GH deficiency, severe IGF-1 deficiency or short stature
  • GH-axis mechanism: 100 · documented: these compounds raise GH or IGF-1; growth gains appeared in some studies of children with deficiency or short stature, and a placebo-controlled GHRP-2 trial found none
  • safety concern: 100 · documented: the Increlex label warnings and FDA's warning on ibutamoren
  • approval for healthy height: 0 · none: mecasermin's label covers only diagnosed pediatric conditions, sermorelin's approval was withdrawn, and ibutamoren is unapproved

sources

  1. DailyMed. Increlex mecasermin injection. Label revised October 2025; posted May 2026. Current canonical DailyMed Increlex label.
  2. FDA. 78 FR 14095. 2013. Geref withdrawal determination.
  3. Thorner MO et al. 1996. PMID 8772599. Once-daily subcutaneous sermorelin in 110 children.
  4. Chen RG et al. Acta Paediatr Suppl. 1993. PMID 8329830. Randomized comparison of GHRH(1-29)-NH2 and growth hormone in 60 children.
  5. Neyzi O et al. Acta Paediatr Suppl. 1993. PMID 8329826. Randomized dose comparison of GHRH(1-29)-NH2 against growth hormone in 43 children.
  6. ClinicalTrials.gov. NCT06948214. Recruiting phase 3 placebo-controlled trial of oral LUM-201 in prepubertal children with GH deficiency.
  7. ClinicalTrials.gov. NCT04614337 (OraGrowtH210). Completed phase 2 trial of oral LUM-201 against daily growth hormone injections in prepubertal children with GH deficiency.
  8. ClinicalTrials.gov. NCT05250063 (OraGrowtH213). Completed open-label phase 2 of LUM-201 in children with GH deficiency after 12 months of daily growth hormone.
  9. ClinicalTrials.gov. Search for LUM-201, ibutamoren, MK-677 or MK-0677, run 24 October 2026. 14 registered studies; the 6 pediatric studies all enroll children with GH deficiency.
  10. Codner E et al. Clinical Pharmacology and Therapeutics. 2001. PMID 11452249. Short-term oral ibutamoren mesylate in 18 prepubertal children with GH deficiency.
  11. FDA. Agebox iKids Growth Day Formula hidden-ingredient notification. September 2025. FDA communication naming ibutamoren as an unapproved hidden ingredient.
  12. Pihoker C et al. J Endocrinol 1997. Intranasal GHRP-2 treatment effects in children with short stature.
  13. Tanaka T et al. Clin Pediatr Endocrinol 2014. Intranasal GHRP-2 did not promote growth in 126 short children with GH deficiency.
  14. Klinger B et al. Eur J Endocrinol. 1996;134(6):716-9. PMID 8766941. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children

keep reading

claim checks

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.